TrendingVideosIndia
Opinions | CommentEditorialsThe MiddleLetters to the EditorReflections
Sports
State | Himachal PradeshPunjabJammu & KashmirHaryanaChhattisgarhMadhya PradeshRajasthanUttarakhandUttar Pradesh
City | ChandigarhAmritsarJalandharLudhianaDelhiPatialaBathindaShaharnama
World | United StatesPakistan
Diaspora
Features | The Tribune ScienceTime CapsuleSpectrumIn-DepthTravelFood
Business | My MoneyAutoZone
News Columns | Kashmir AngleJammu JournalInside the CapitalHimachal CallingHill View
Don't Miss
Advertisement

Combining AstraZeneca and mRNA Covid19 vaccines is effective: Danish study

Unlock Exclusive Insights with The Tribune Premium

Take your experience further with Premium access. Thought-provoking Opinions, Expert Analysis, In-depth Insights and other Member Only Benefits
Yearly Premium ₹999 ₹349/Year
Yearly Premium $49 $24.99/Year
Advertisement

Copenhagen, August 2 

Advertisement

Combining AstraZeneca’s Covid-19 vaccine with a second dose from either Pfizer-BioNTech or Moderna’s jab provides “good protection”, Denmark’s State Serum Institute said on Monday.

Advertisement

A growing number of countries are looking at switching to different Covid-19 vaccines for second doses, a measure particularly necessary in Denmark after health authorities discontinued inoculations with AstraZeneca’s vaccine in April over rare side-effect concerns.

More than 144,000 Danes, mostly frontline personnel in the health sector and the elderly, received their first jab with AstraZeneca’s vaccine but were subsequently vaccinated with either Pfizer-BioNTech or Moderna’s shots.

“The study shows that fourteen days after a combined vaccination program, the risk of infection with SARS-CoV-2 is reduced by 88 per cent compared to unvaccinated individuals,” the State Serum Institute (SSI) said.

Advertisement

That is a “high efficacy”, SSI added, comparable to the 90% efficacy rate of two doses from Pfizer-BioNTech’s vaccine, confirmed in a different Danish study.

The study, published last week, covered a span of more than five months between February and June this year, a period in which the Alpha-variant of the coronavirus was predominant.

It could not conclude whether the same protection applied to the Delta-variant, which is now the most widespread in Denmark.

It also provided no efficacy data on Covid-19 related deaths or hospitalisations, since none took place following the combined vaccination programme.

— Reuters

Advertisement
Show comments
Advertisement